1. Home
  2. AIRI vs SNGX Comparison

AIRI vs SNGX Comparison

Compare AIRI & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Air Industries Group

AIRI

Air Industries Group

HOLD

Current Price

$2.88

Market Cap

13.5M

Sector

Industrials

ML Signal

HOLD

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$1.57

Market Cap

13.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIRI
SNGX
Founded
1979
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.5M
13.8M
IPO Year
N/A
1987

Fundamental Metrics

Financial Performance
Metric
AIRI
SNGX
Price
$2.88
$1.57
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
27.5K
304.6K
Earning Date
11-14-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$50,031,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.53
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.77
$1.09
52 Week High
$4.70
$6.23

Technical Indicators

Market Signals
Indicator
AIRI
SNGX
Relative Strength Index (RSI) 39.79 52.12
Support Level $2.95 $1.55
Resistance Level $3.15 $1.70
Average True Range (ATR) 0.11 0.11
MACD 0.01 0.02
Stochastic Oscillator 14.26 62.69

Price Performance

Historical Comparison
AIRI
SNGX

About AIRI Air Industries Group

Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: